http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021232072-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b5f5d49c93cab8d0176c686ed2cf2aa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-9066 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-9068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-9066 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-9068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 |
| filingDate | 2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_518602dbb8260837bef4a2f048db3fb8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1249fa526500a49ad7bd5b606317e00f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ad3275e6d66cba11a762085c065a856 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87db5e42c57e07c47a76b70a3c61f96c |
| publicationDate | 2021-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021232072-A1 |
| titleOfInvention | Tricomponent solid lipid nano-composition comprising curcumin, ginger oleoresin, rutin having a cancer-cell-killing property and method of preparing the same |
| abstract | The present invention relates to a composition with oncological therapeutic effects prepared according to the organic sol-gel nanotechnology from a solid lipid nano tricomponent combination: nano curcumin, nano ginger oleoresin, and nano rutin. These pharmaceutical ingredients are all extracted from natural sources. Via testing, the composition of the present invention has shown that all has low toxicity and great bioavailability, highly enhanced cancer- cell killing effects, wherein the cytotoxic tests of the composition have been performed on many different cell lines in vitro and in Lewis Lung carcinoma (LLC) tumor-induced mouse models. The composition exhibits the cytotoxicity against breast cancer cells (MCF7), hepatocarinoma cells (HepG2), lung cancer cells (SK-LU-1), cocorectal adenocarcinoma cells (SW480), and human leukemia cells (HL-60). Further, mice having LLC tumor that are treated with the composition (600 mg/kg body weight [bw]) shows significant reduction in tumor growth (P <0.05), longer average survival time (34.05 days), and improved liver functions. |
| priorityDate | 2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 106.